Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2014; 111(03): 559-561DOI: 10.1160/TH13-06-0510 Letters to the Editor Schattauer GmbH Intermediate doses of low-molecular-weight heparin for the long-term treatment of pregnancy thromboembolism. A systematic review Esteban Gándara * 1 Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa - The Ottawa Hospital, Ottawa, Ontario, Canada 2 Clinical Epidemiology Unit, Ottawa Health Research Institute, Ottawa, Ontario, Canada , Marc Carrier * 1 Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa - The Ottawa Hospital, Ottawa, Ontario, Canada 2 Clinical Epidemiology Unit, Ottawa Health Research Institute, Ottawa, Ontario, Canada , Marc A. Rodger * 1 Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa - The Ottawa Hospital, Ottawa, Ontario, Canada 2 Clinical Epidemiology Unit, Ottawa Health Research Institute, Ottawa, Ontario, Canada › Author Affiliations Recommend Article Abstract Buy Article Note: The contact information for Drs. Gandara and Carrier is the same as for Dr. Rodger. Their e-mail addresses are egandara@ohri.ca and mcarrier@ohri.ca, respectively. Full Text References References 1 Bates SM, Greer I, Middeldorp S. et al. VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; Suppl e691S-e736S. 2 Abou-Nassar K, Kovacs MJ, Kahn SR. et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98: 163-171. 3 Sephton V, Farquharson RG, Topping J. et al. A Longitudinal Study of Maternal Dose Response to Low Molecular Weight Heparin in Pregnancy. Obstet Gynecol 2003; 101: 1307-1311. 4 Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191: 1024-1029. 5 Arya R. How I manage venous thromboembolism in pregnancy. Br J Haematol 2011; 153: 698-708. 6 Middeldorp S. How I treat pregnancy-related venousthromboembolism. Blood 2011; 118: 5394-5400. 7 Hull RD, Townshend G. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: An update of the evidence. Thromb Hae-most 2013; 110: 14-22. 8 Kearon C, Akl EA, Comerota AJ. et al. Antithrom-botic Therapy for VTE Disease Antithrombotic Therapy for VTE Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-e494S. 9 Rodger M. Evidence base for the management of venous thromboembolism in pregnancy. Hematology Am Soc Hematol Educ Program 2010; 173-180. 10 Bauersachs RM. Treatment of venous thromboem-bolism during pregnancy. Thromb Res 2009; 123: S45-S50. 11 Miller S, Lester F, Hensleigh P. CEU: Prevention and Treatment of Postpartum Hemorrhage: New Advances for Low-Resource Settings. J Midwifery Womens Health 2004; 49: 283-292. 12 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009 Report. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 13 Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care; 6: 5-30. 14 Barillari G, Springolo F, Daminiato R. et al. Safety and efficacy of nadroparin for the management of venous thromboembolism or thrombophilia in pregnancy. J Thromb Haemost. 2007 05. Abstract P-S-623. 15 Daskalakis G, Antsaklis A, Papageorgiou I. et al. Thrombosis prophylaxis after treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 1997; 74: 165-167. 16 Lyall H, Myers B. Incidence and management of 82 cases of pregnancy-associated venous throm-boembolism occurring at a single centre--comparison with Voke et al. Br J Haematol 2008; 142: 309-311. 17 Mitic G, Povazan L, Lucic AM. Treatment of pregnancy related venous thromboembolism. Med Pregl 2009; 62: 346-351. 18 Smith MP, Norris LA, Steer PJ. et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190: 495-501. 19 Ulander VM, Stenqvist P, Kaaja R. Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy. Thrombosis Res 2002; 106: 13-17. 20 Rodie VA, Thomson AJ, Stewart FM. et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. Br J Obstet Gynecol 2002; 109: 1020-1024. 21 Voke J, Keidan J, Pavord S. et al. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007; 139: 545-558. 22 Knight M. UKOSS.. Antenatal pulmonary embolism: risk factors, management and outcomes. Br J Obstet Gynecol 2008; 115: 453-461. 23 Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1: 1906-1913. 24 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407. 25 Romualdi E, Dentali F, Rancan E. et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analy-sis of the literature. J Thromb Haemost 2013; 11: 270-281. Supplementary Material Supplementary Material Online Supplementary Material (PDF)
